Why the study?
To evaluate clinical outcomes, echocardiographic features, and the efficacy and safety of sacubitril/valsartan compared to valsartan across age groups in PARAGON-HF.
Does sacubitril/valsartan improve clinical outcomes compared to valsartan in patients with heart failure with preserved ejection fraction across age groups?
Does sacubitril/valsartan improve clinical outcomes compared to valsartan in patients with heart failure with preserved ejection fraction across age groups?
The treatment benefits of sacubitril/valsartan compared to valsartan are retained in older patients with HFpEF, although they experience more adverse events and hypotension.
Answers are grounded in this paper and cite their sources.
Benefits retained in older HFpEF patients despite higher events; extends RCT efficacy data to this high-risk subgroup.
AIMS: To evaluate clinical outcomes, echocardiographic features, and the efficacy and safety of sacubitril/valsartan compared to valsartan across age groups in the PARAGON-HF trial. METHODS AND Older patients had smaller left ventricular chamber sizes, higher LVEF, and were more likely to have abnormal measures of diastolic function. CONCLUSION: Older patients with HF with preserved ejection fraction had higher event rates than younger patients, more adverse events overall, and more hypotension when treated with sacubitril/valsartan; however, the treatment benefits of sacubitril/valsartan were retained in older patients.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: